The granted claims of the patent include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents. They are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, attention deficient hyperactivity disorder (ADHD), huntington’s disease, parkinson and schizophrenia.
With the new patent, Suven has a total of eight granted European product patents for its NCEs in CNS therapy. All the 8 EPO patents have been validated in the 37 member countries of Europe including major markets like Germany, Switzerland, Denmark, Spain, France, United Kingdom, Italy, Netherlands, Poland, Sweden and Finland etc.
The granted patents are exclusive intellectual property of Suven and are achieved through the internal drug discovery research efforts. Products out of these inventions may be out-licensed at various phases of pre-clinical and clinical development.
Venkat Jasti, CEO of Suven, said: “We are very pleased by the grant of this patent to Suven by European Patent Office for our pipeline of molecules in CNS arena that are being developed for cognitive disorders which has an estimated $20bn market potential globally.”